HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent

Hdl Handle:
http://hdl.handle.net/10675.2/643
Title:
HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent
Authors:
Qiao, Jingjuan; Li, Shunyi; Wei, Lixia; Jiang, Jie; Long, Robert; Mao, Hui; Wei, Ling; Wang, Liya; Yang, Hua; Grossniklaus, Hans E.; Liu, Zhi-Ren; Yang, Jenny J.
Abstract:
The application of magnetic resonance imaging (MRI) to non-invasively assess disease biomarkers has been hampered by the lack of desired contrast agents with high relaxivity, targeting capability, and optimized pharmacokinetics. We have developed a novel MR imaging probe targeting to HER2, a biomarker for various cancer types and a drug target for anti-cancer therapies. This multimodal HER20targeted MR imaging probe integrates a de novo designed protein contrast agent with a high affinity HER2 affibody and a near IR fluorescent dye. Our probe can differentially monitor tumors with different expression levels of HER2 in both human cell lines and xenograft mice models. In addition to its 100-fold higher dose efficiency compared to clinically approved non-targeting contrast agent DTPA, our developed agent also exhibits advantages in crossing the endothelial boundary, tissue distribution, and tumor tissue retention over reported contrast agents as demonstrated by even distribution of the imaging probe across the entire tumor mass. This contrast agent will provide a powerful tool for quantitative assessment of molecular markers, and improved resolution for diagnosis, prognosis and drug discovery.
Editors:
Du, Quansheng
Citation:
PLoS One. 2011 Mar 24; 6(3):e18103
Issue Date:
24-Mar-2011
URI:
http://hdl.handle.net/10675.2/643
DOI:
10.1371/journal.pone.0018103
PubMed ID:
21455310
PubMed Central ID:
PMC3063795
Type:
Article
ISSN:
1932-6203
Appears in Collections:
Department of Neurology: Faculty Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorQiao, Jingjuanen_US
dc.contributor.authorLi, Shunyien_US
dc.contributor.authorWei, Lixiaen_US
dc.contributor.authorJiang, Jieen_US
dc.contributor.authorLong, Roberten_US
dc.contributor.authorMao, Huien_US
dc.contributor.authorWei, Lingen_US
dc.contributor.authorWang, Liyaen_US
dc.contributor.authorYang, Huaen_US
dc.contributor.authorGrossniklaus, Hans E.en_US
dc.contributor.authorLiu, Zhi-Renen_US
dc.contributor.authorYang, Jenny J.en_US
dc.contributor.editorDu, Quansheng-
dc.date.accessioned2012-10-26T16:26:58Z-
dc.date.available2012-10-26T16:26:58Z-
dc.date.issued2011-03-24en_US
dc.identifier.citationPLoS One. 2011 Mar 24; 6(3):e18103en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid21455310en_US
dc.identifier.doi10.1371/journal.pone.0018103en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/643-
dc.description.abstractThe application of magnetic resonance imaging (MRI) to non-invasively assess disease biomarkers has been hampered by the lack of desired contrast agents with high relaxivity, targeting capability, and optimized pharmacokinetics. We have developed a novel MR imaging probe targeting to HER2, a biomarker for various cancer types and a drug target for anti-cancer therapies. This multimodal HER20targeted MR imaging probe integrates a de novo designed protein contrast agent with a high affinity HER2 affibody and a near IR fluorescent dye. Our probe can differentially monitor tumors with different expression levels of HER2 in both human cell lines and xenograft mice models. In addition to its 100-fold higher dose efficiency compared to clinically approved non-targeting contrast agent DTPA, our developed agent also exhibits advantages in crossing the endothelial boundary, tissue distribution, and tumor tissue retention over reported contrast agents as demonstrated by even distribution of the imaging probe across the entire tumor mass. This contrast agent will provide a powerful tool for quantitative assessment of molecular markers, and improved resolution for diagnosis, prognosis and drug discovery.en_US
dc.rightsQiao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectResearch Articleen_US
dc.subjectBiologyen_US
dc.subjectBiochemistryen_US
dc.subjectMolecular Cell Biologyen_US
dc.subjectChemistryen_US
dc.subjectChemical Biologyen_US
dc.subjectMedicineen_US
dc.subjectObstetrics and Gynecologyen_US
dc.subjectBreast Canceren_US
dc.subjectOncologyen_US
dc.subjectCancers and Neoplasmsen_US
dc.subjectGynecological Tumorsen_US
dc.subjectOvarian Canceren_US
dc.subjectCancer Detection and Diagnosisen_US
dc.subjectRadiologyen_US
dc.subjectDiagnostic Radiologyen_US
dc.subjectMagnetic Resonance Imagingen_US
dc.titleHER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agenten_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3063795en_US
dc.contributor.corporatenameDepartment of Neurology-
dc.contributor.corporatenameCollege of Graduate Studies-

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.